Denmark's Anapa Biotech Applies Primer-Modification Tech to MRSA Assay; Discloses NextGen Molecule | GenomeWeb

SAN FRANCISCO — An executive from Danish biotech firm Anapa Biotech this week disclosed new data demonstrating how its proprietary twisted intercalating nucleic acid (TINA) molecules for modifying real-time PCR primers increased the efficiency and analytical sensitivity of a multiplexed real-time PCR assay for the detection of Staphylococcus aureus and methicillin-resistant S. aureus.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

Widespread genome sequencing might not be justified just yet, USA Today reports.